ICON Public (NASDAQ:ICLR – Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 13.900-14.100 for the period, compared to the consensus earnings per share estimate of 15.060. The company issued revenue guidance of $8.3 billion-$8.3 billion, compared to the consensus revenue estimate of $8.5 billion. ICON Public also updated its FY24 guidance to $13.90-14.10 EPS.
Wall Street Analysts Forecast Growth
A number of equities analysts have commented on ICLR shares. Leerink Partners initiated coverage on shares of ICON Public in a research report on Wednesday, September 18th. They set an “outperform” rating and a $379.00 price objective for the company. Robert W. Baird dropped their target price on ICON Public from $368.00 to $340.00 and set an “outperform” rating on the stock in a research report on Friday, September 20th. Truist Financial reduced their price target on ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a report on Monday, October 14th. Evercore ISI cut their price objective on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a research report on Tuesday, October 8th. Finally, Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a research report on Wednesday, September 18th. Two equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus target price of $346.09.
Read Our Latest Research Report on ICON Public
ICON Public Price Performance
ICON Public (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings data on Wednesday, July 24th. The medical research company reported $3.75 EPS for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.14 billion. During the same period in the prior year, the firm posted $2.96 EPS. The business’s revenue for the quarter was up 4.1% on a year-over-year basis. On average, analysts anticipate that ICON Public will post 14.54 EPS for the current year.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Stories
- Five stocks we like better than ICON Public
- Overbought Stocks Explained: Should You Trade Them?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Differences Between Momentum Investing and Long Term Investing
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Quiet Period Expirations Explained
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.